Saturday, October 3, 2026

GBP/EUR Over 1% Down In The Last 21 Sessions

ViaNews Editorial Team

August 21, 2024

GBP/EUR Over 1% Down In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.51% for the last 21 sessions. At 20:10 EST on Tuesday, 20 August, GBP/EUR (GBPEUR) is $1.17.

GBP/EUR's yearly highs and lows, it's 2.674% up from its 52-week low and 1.803% down from its 52-week high.

News about

  • Eur/usd: FX options markets suggest some active buying – ING. According to FXStreet on Tuesday, 20 August, "At the heart of the story is whether EUR/USD willbreak out of an 18-month trading range, which has largely contained EUR/USD between 1.05 and 1.11, ING's FX strategist Chris Turner notes.", "The one-month risk reversal -the price of a EUR/USD call option over an equivalent put option -is moving deeper in favour of euro calls. "
  • Eur/usd: A run towards 1.1 near term is possible – scotiabank. According to FXStreet on Tuesday, 20 August, "The Euro (EUR) is showing a marginal loss on the day on the screens but EUR/USD has essentially moved sideways in a narrow range overnight as the market consolidates around the EUR's highest point since the start of the year, Scotiabank's Chief FX Strategist Shaun Osborne notes.", "While much attention falls on the Fed policy outlook as a driver of EUR/USD gains, the ECB cannot be overlooked. "
  • Eur/usd: new range? – rabobank. According to FXStreet on Tuesday, 20 August, "As we argued earlier this month, we see upside risks for EUR/USD as likely to be associated with a softer USD rather than a broadly stronger EUR. ", "On balance, while we can not rule out another dip to the EUR/USD1.08 area in the weeks ahead, we expect EUR/USD to 1.09/1.10 area to become more comfortable for EUR/USD in the coming months."

More news about GBP/EUR (GBPEUR).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com